Rovin Capital UT ADV Invests $393,000 in West Pharmaceutical Services, Inc. (NYSE:WST)

Rovin Capital UT ADV bought a new stake in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,754 shares of the medical instruments supplier's stock, valued at approximately $393,000.

Other large investors have also modified their holdings of the company. IFP Advisors Inc increased its holdings in West Pharmaceutical Services by 150.9% in the 4th quarter. IFP Advisors Inc now owns 133 shares of the medical instruments supplier's stock valued at $45,000 after purchasing an additional 80 shares during the last quarter. QRG Capital Management Inc. boosted its position in shares of West Pharmaceutical Services by 24.6% during the fourth quarter. QRG Capital Management Inc. now owns 1,871 shares of the medical instruments supplier's stock worth $613,000 after buying an additional 369 shares during the period. Private Trust Co. NA grew its stake in shares of West Pharmaceutical Services by 138.6% in the fourth quarter. Private Trust Co. NA now owns 136 shares of the medical instruments supplier's stock valued at $45,000 after buying an additional 79 shares in the last quarter. Metis Global Partners LLC grew its stake in shares of West Pharmaceutical Services by 3.4% in the fourth quarter. Metis Global Partners LLC now owns 6,430 shares of the medical instruments supplier's stock valued at $2,106,000 after buying an additional 211 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its holdings in shares of West Pharmaceutical Services by 37.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 914 shares of the medical instruments supplier's stock valued at $301,000 after buying an additional 248 shares during the period. Institutional investors and hedge funds own 93.90% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on WST shares. Barclays assumed coverage on West Pharmaceutical Services in a research report on Tuesday, June 24th. They issued an "equal weight" rating and a $245.00 target price for the company. Evercore ISI began coverage on shares of West Pharmaceutical Services in a report on Tuesday, March 18th. They issued an "outperform" rating and a $275.00 price objective for the company. Stephens raised shares of West Pharmaceutical Services to a "strong-buy" rating in a research note on Monday, April 21st. Finally, Citigroup reiterated a "buy" rating on shares of West Pharmaceutical Services in a report on Thursday, May 22nd. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $320.00.

West Pharmaceutical Services Stock Up 0.2%

NYSE:WST traded up $0.53 during mid-day trading on Friday, hitting $221.75. The stock had a trading volume of 370,766 shares, compared to its average volume of 735,377. West Pharmaceutical Services, Inc. has a twelve month low of $187.43 and a twelve month high of $352.33. The stock has a 50-day simple moving average of $215.83 and a two-hundred day simple moving average of $249.79. The company has a current ratio of 2.77, a quick ratio of 2.03 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $15.93 billion, a PE ratio of 34.81, a PEG ratio of 5.47 and a beta of 1.09.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $1.45 EPS for the quarter, beating analysts' consensus estimates of $1.22 by $0.23. The company had revenue of $698.00 million for the quarter, compared to the consensus estimate of $685.24 million. West Pharmaceutical Services had a net margin of 16.13% and a return on equity of 18.23%. The company's quarterly revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.56 EPS. On average, equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 6th. Shareholders of record on Wednesday, July 30th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.38%. The ex-dividend date of this dividend is Wednesday, July 30th. West Pharmaceutical Services's dividend payout ratio (DPR) is 13.19%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.